

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3674611

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
TAISHO PHARMACEUTICAL CO., LTD.	12/03/2015
RECEIVING PARTY DATA	
Name:	NISSAN CHEMICAL INDUSTRIES, LTD.
Street Address:	7-1, KANDA NISHIKICHO 3-CHOME, CHIYODA-KU
City:	TOKYO
State/Country:	JAPAN
PROPERTY NUMBERS Total: 2	
Property Type	Number
Patent Number:	8822503
Application Number:	14442157
CORRESPONDENCE DATA	
Fax Number:	(202)293-7860
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	202-293-7060
Email:	vfletcher@sughrue.com
Correspondent Name:	SUGHRUE MION, PLLC
Address Line 1:	2100 PENNSYLVANIA AVENUE, N.W.
Address Line 2:	SUITE 800
Address Line 4:	WASHINGTON, D.C. 20037
ATTORNEY DOCKET NUMBER:	Q219708
NAME OF SUBMITTER:	VANESSA FLETCHER
SIGNATURE:	/Vanessa Fletcher/
DATE SIGNED:	12/29/2015
Total Attachments: 1	
source=Q219708AssignmentexecutedTransferofRights#page1.tif	

U.S.
E 5201-02
E 6210-20
P 780, 7804

Docket No. Q124029 and Q219708
For Non-U.S. Clients

Assignment

Whereas, TAISHO PHARMACEUTICAL CO., LTD., of 24-1, Takada 3-Chome, Toshima-Ku, Tokyo, JAPAN, hereinafter referred to as the "Assignor," is the owner of an undivided share of the entire right, title, and interest in and to:

- (1) U.S. Patent No. 8,822,503 entitled "2-PYRIDONE COMPOUNDS", by virtue of an assignment from the inventors thereof recorded on June 14, 2011, at Reel/Frame 026443/0488; and
- (2) U.S. Application No. 14/442,157 entitled "2-PYRIDONE COMPOUND", by virtue of an assignment from the inventors thereof recorded on June 8, 2015, at Reel/Frame 035802/0491;

Whereas, NISSAN CHEMICAL INDUSTRIES, LTD., of 7-1, Kanda Nishikicho 3-Chome, Chiyoda-Ku, Tokyo, JAPAN, hereinafter referred to as the "Assignee," desires to acquire said undivided share of the entire right, title, and interest in said United States Patent and Application;

Now therefore, for valuable consideration, receipt whereof is hereby acknowledged,

We, the above named Assignor, hereby sell, assign and transfer to the above named Assignee, their successors and assigns, our undivided share of the entire right, title and interest in and to said United States Patent No. 8,822,503 and United States Application No. 14/442,157, and the inventions disclosed therein for the United States of America, including the right to claim priority under 35 U.S.C. §119, and we request the Director of the U.S. Patent and Trademark Office to issue any continuing applications, reissue applications and reexamination applications based thereon to the above-named Assignor, its successors and assigns; and we will execute without further consideration all papers deemed necessary by the above named Assignor in connection with United States Patent No. 8,822,503 and United States Application No. 14/442,157, when called upon to do so by the above named Assignee.

Date: December 3rd, 2015

(signature of assignor) 

(name of assignor's representative) Shigeru UEHARA

(title) President

TAISHO PHARMACEUTICAL CO., LTD.